PRESS RELEASE published on 02/27/2023 at 08:00, 3 years 6 months ago DEFENCE’S PIPELINE ADVANCES TO MULTIPLE PHASE I CLINICAL TRIALS
PRESS RELEASE published on 02/21/2023 at 08:00, 3 years 6 months ago Defence Therapeutics Inc.: DEFENCE DELEGATES CITY OF HOPE TO INITIATE IND FILLING FOR ITS ACCUTOXTM CANCER PROGRAM
PRESS RELEASE published on 02/06/2023 at 08:00, 3 years 6 months ago DEFENCE MANUFACTURING ITS ARM VACCINE IN PREPARATION FOR PHASE I CLINICAL TRIAL AGAINST SOLID TUMORS
PRESS RELEASE published on 02/03/2023 at 08:00, 3 years 6 months ago DEFENCE THERAPEUTICS AND CQDM FUND THE DEVELOPMENT OF A NEW CANCER VACCINE PLATFORM
PRESS RELEASE published on 01/31/2023 at 08:00, 3 years 7 months ago Defence Therapeutics Inc.: DEFENCE’S LUNG CANCER GLP TOX STUDY ON ITS INTRANASAL ACCUTOXTM FORMULATION ADVANCES
PRESS RELEASE published on 01/24/2023 at 08:00, 3 years 7 months ago DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED
PRESS RELEASE published on 01/23/2023 at 08:00, 3 years 7 months ago Defence Therapeutics Inc.: DEFENCE TO PRESENT AT THE 9TH ANNUAL IMMUNO-ONCOLOGY 360º SUMMIT IN NEW-YORK FEBRUARY 7-10, 2023
PRESS RELEASE published on 01/16/2023 at 08:00, 3 years 7 months ago Defence Therapeutics Inc.: DEFENCE ACCUMTM ACCEPTED US PATENT TO BOLSTER ITS VACCINE PLATFORM TECHNOLOGY IP
PRESS RELEASE published on 01/10/2023 at 08:00, 3 years 7 months ago Defence Therapeutics Inc.: mRNA WITH DEFENCE’S ACCUMTM PROGRAM HAS BEEN INITIATED
Published on 08/31/2026 at 17:22, 46 minutes ago ACCESS Newswire Expands the Marketplace with Two New Partners: TVEyes and Listicle Liaison
Published on 08/31/2026 at 15:50, 2 hours 18 minutes ago Sarama Resources - Grant of Equity Incentives
Published on 08/31/2026 at 15:00, 3 hours 8 minutes ago Super Copper Featured at OTC Markets' Virtual Investor Conference, Presentation Replay Now Available
Published on 08/31/2026 at 14:30, 3 hours 38 minutes ago While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
Published on 08/31/2026 at 17:47, 21 minutes ago clearvise AG with successful Annual General Meeting 2026
Published on 08/31/2026 at 16:40, 1 hour 28 minutes ago Grêle : la Vaudoise se mobilise face à plus de 2’000 sinistres attendus
Published on 08/31/2026 at 16:09, 1 hour 59 minutes ago Mayr-Melnhof Karton AG: MM Group secures EcoVadis Platinum, ranking among global top 1 % for sustainability
Published on 08/31/2026 at 15:40, 2 hours 28 minutes ago EQS-Adhoc: SCP Standard Capital Partners AG expects to realize a book gain of approximately EUR 35 million from the acquisition of VANEA Technologies GmbH and Nocturne Technologies GmbH
Published on 08/31/2026 at 15:10, 2 hours 58 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/31/2026 at 18:00, 8 minutes ago MISE A DISPOSITION RAPPORT FINANCIER ANNUEL 2025/2026
Published on 08/31/2026 at 17:45, 23 minutes ago Disclosure of transactions in own shares from August 24 to August 28, 2026
Published on 08/31/2026 at 17:45, 23 minutes ago Déclaration hebdomadaire d'opérations effectuées du 24 au 28 août 2026
